Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Wild-type Colon Cancer”

120 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 120 results

Large-scale testing (Phase 3)Study completedNCT03206151
What this trial is testing

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd 520
Very early researchActive Not RecruitingNCT06011772
What this trial is testing

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Colo-rectal Cancer
Roswell Park Cancer Institute 2
Early research (Phase 1)Study completedNCT03317119
What this trial is testing

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Carcinoma+22 more
City of Hope Medical Center 26
Not applicableStudy completedNCT05396807
What this trial is testing

REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients

Who this might be right for
Metastatic Colon Cancer
University of Rome Tor Vergata 106
Large-scale testing (Phase 3)Looking for participantsNCT06226857
What this trial is testing

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsChemotherapy EffectMolecular Sequence Variation
City Clinical Oncology Hospital No 1 355
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Testing effectiveness (Phase 2)Temporarily pausedNCT05062889
What this trial is testing

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Who this might be right for
Stage II Colon CancerStage III Colon CancerHER2-positive Colon Cancer+1 more
Gruppo Oncologico del Nord-Ovest 477
Testing effectiveness (Phase 2)Study completedNCT04224415
What this trial is testing

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

Who this might be right for
Metastatic Colorectal Cancer
Yuhong Li 35
Testing effectiveness (Phase 2)UnknownNCT05684211
What this trial is testing

Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd. 84
Testing effectiveness (Phase 2)Looking for participantsNCT06776757
What this trial is testing

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center 30
Large-scale testing (Phase 3)Study completedNCT03231722
What this trial is testing

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 435
Testing effectiveness (Phase 2)Study completedNCT04513951
What this trial is testing

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 62
Testing effectiveness (Phase 2)UnknownNCT02717923
What this trial is testing

A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
Huazhong University of Science and Technology 50
Testing effectiveness (Phase 2)Study completedNCT01126112
What this trial is testing

Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer

Who this might be right for
Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 33
Post-approval studies (Phase 4)Not Yet RecruitingNCT07094893
What this trial is testing

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Who this might be right for
Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 280
Testing effectiveness (Phase 2)Study completedNCT04425239
What this trial is testing

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IV
National Cancer Institute, Naples 151
Early research (Phase 1)Ended earlyNCT03275974
What this trial is testing

Glutamine PET Imaging Colorectal Cancer

Who this might be right for
RAS Wild TypeStage IV Colorectal CancerStage IVA Colorectal Cancer+1 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT02399943
What this trial is testing

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerKRAS WildtypeNRAS Wildtype+1 more
University Health Network, Toronto 14
Testing effectiveness (Phase 2)UnknownNCT05799443
What this trial is testing

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Fujian Cancer Hospital 23
Testing effectiveness (Phase 2)Study completedNCT05278728
What this trial is testing

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Who this might be right for
Colorectal Cancer
Biotech Pharmaceutical Co., Ltd. 31
Load More Results